

## DAFTAR PUSTAKA

- Abid, K., Shah, I., Sheikh, G., 2017. Cutaneous manifestations of polycystic ovary syndrome: a cross sectional clinical stud. *Indian Dermatol Online Journal*.
- Al-Azemi, M., Omu, F.E., Omu, A.E., 2004. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. *Arch Gynecol Obstet* 270, 205–210. <https://doi.org/10.1007/s00404-003-0537-2>
- Althuis, M.D., Moghissi, K.S., Westhoff, C.L., Scoccia, B., Lamb, E.J., Lubin, J.H., Brinton, L.A., 2005. Uterine cancer after use of clomiphene citrate to induce ovulation. *Am J Epidemiol* 161, 607–615. <https://doi.org/10.1093/aje/kwi084>
- Anonim, 2013. Riset Kesehatan Dasar. Kementrian Kesehatan Republik Indonesia, Jakarta.
- Apridonidze, T., Essah, P., Iuorno, M., Nestler, J., 2005. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *Essah PA, Nestler JE. 2005 Apr; 90(4):1929-35. J Clin Endocrinol Metab*.
- Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H., Futterweit, W., Janssen, O., Legro, R., Norman, R., Taylor, A., Witchel, S., 2006. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *Androgen Excess Society. J Clin Endocrinol Metab*.
- Badawy, A., Gibreal, A., 2011. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. *Eur J Obstet Gynecol Reprod Biol* 159, 151–154. <https://doi.org/10.1016/j.ejogrb.2011.07.015>
- Barber, T.M., McCarthy, M.I., Wass, J. a. H., Franks, S., 2006. Obesity and polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 65, 137–145. <https://doi.org/10.1111/j.1365-2265.2006.02587.x>
- Bjornholt, S.M., Kjaer, S.K., Nielsen, T.S.S., Jensen, A., 2015. Risk for borderline ovarian tumours after exposure to fertility drugs: Results of a population-based cohort study. *Human Reproduction* 30, 222–231. <https://doi.org/10.1093/humrep/deu297>
- Brinton, L.A., Lamb, E.J., Moghissi, K.S., Scoccia, B., Althuis, M.D., Mabie, J.E., Westhoff, C.L., 2004a. Ovarian cancer risk after the use of ovulation-stimulating drugs. *Obstet Gynecol* 103, 1194–1203. <https://doi.org/10.1097/01.AOG.0000128139.92313.74>
- Brinton, L.A., Scoccia, B., Moghissi, K.S., Westhoff, C.L., Althuis, M.D., Mabie, J.E., Lamb, E.J., 2004b. Breast cancer risk associated with ovulation-stimulating drugs. *Hum Reprod* 19, 2005–2013. <https://doi.org/10.1093/humrep/deh371>
- Brinton, L.A., Scoccia, B., Moghissi, K.S., Westhoff, C.L., Niwa, S., Ruggieri, D., Trabert, B., Lamb, E.J., 2014. Long-Term Relationship of Ovulation-Stimulating Drugs to Breast Cancer Risk. *Cancer Epidemiol Biomarkers Prev* 23, 584–593. <https://doi.org/10.1158/1055-9965.EPI-13-0996>
- Brinton, L.A., Westhoff, C.L., Scoccia, B., Lamb, E.J., Trabert, B., Niwa, S.,

- Moghissi, K.S., 2013. Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort. *Hum Reprod* 28, 2813–2821. <https://doi.org/10.1093/humrep/det323>
- Burghen, G., Givens, J., Kitabchi, A., 1980. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. *J Clin Endocrinol Metab.*
- Calderon-Margalit, R., Friedlander, Y., Yanetz, R., Kleinhaus, K., Perrin, M.C., Manor, O., Harlap, S., Paltiel, O., 2009. Cancer Risk After Exposure to Treatments for Ovulation Induction. *Am J Epidemiol* 169, 365–375. <https://doi.org/10.1093/aje/kwn318>
- Cascella, T., Palomba, S., Tauchmanova, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Calao, A., Lombardi, G., Orio, F., 2006. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. Cascella T, Palomba S, Tauchmanovà L, Manguso F, Di Biase S, Labella D, Giallauria F, Vigorito C, Colao A, Lombardi G, Orio F 2006 Nov; 91(11):4395-400. *Jornal Clinical Endocrinol Metab.*
- Chang, A., Abdullah, S., Jain, T., HG, H., Das, S., McGuire, D., Auchus, R., deLemon, J., 2007. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. *J Am Coll Cardiol.*
- Coyral-Castel, S., Tosca, L., Ferreira, G., 2008. The effect of AMP-activated kinase activation on gonadotrophin-releasing hormone secretion in GT1-7 cell and its potential role in hypothalamic regulation of the oestrous cyclicity in rats. *Journal Neuroendocrinol.*
- Diamanti-Kandarakis, E., Kandarakis, H., Legro, R., 2006. The role of genes and environment in the etiology of PCOS. *Endocrine.*
- Ding, T., Hardiman, P.J., Petersen, I., Wang, F.-F., Qu, F., Balo, G., 2017. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. *Octotarget* 8.
- dos Santos Silva, I., Wark, P.A., McCormack, V.A., Mayer, D., Overton, C., Little, V., Nieto, J., Hardiman, P., Davies, M., MacLean, A.B., 2009. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. *Br J Cancer* 100, 1824–1831. <https://doi.org/10.1038/sj.bjc.6605086>
- Du, D., Li, X., 2013. The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. *International Journal of Clinical and Experimental Medicine.*
- Ehrmann, D., 2005. Polycystic ovary syndrome. *N Engl J Med.*
- Escobar-Morreale, H., Luque-Ramirez, M., Gonzalez, F., 2011. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. *Fertil Steril.*
- Farimani Sanoee, M., Neghab, N., Rabiee, S., Amiri, I., 2011. Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome. *Iran J Med Sci* 36, 90–95.
- Farooq, M., Alwan, Y., Ayaz, A., 2013. Metformin-clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome. *J Hum Reprod Sci* 6, 15. <https://doi.org/10.4103/0974-1208.112372>

- Farzinvash, Z., 2018. A young woman with sudden visual field shimmering: A case report. *Indian J Ophthalmol* 66, 1504–1505. [https://doi.org/10.4103/ijo.IJO\\_515\\_18](https://doi.org/10.4103/ijo.IJO_515_18)
- Fausser, B., Pache, T., Lamberts, S., Hop, W., de Jong, F., Dahl, K., 1991. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. *J Clin Endocrinol Metab*.
- Fleming, R., Hopkinson, Z.E., Wallace, A.M., Greer, I.A., Sattar, N., 2002. Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial. *The Journal of Clinical Endocrinology & Metabolism* 87, 569–574. <https://doi.org/10.1210/jcem.87.2.8261>
- Gainder, S., Sharma, B., 2019. Update on Management of Polycystic Ovarian Syndrome for Dermatologists. *Indian Dermatol Online J* 10, 97–105. [https://doi.org/10.4103/idoj.IDOJ\\_249\\_17](https://doi.org/10.4103/idoj.IDOJ_249_17)
- Genazzani, A.D., Ricchieri, F., Lanzoni, C., 2010. Use of Metformin in the Treatment of Polycystic Ovary Syndrome. *Womens Health (Lond Engl)* 6, 577–593. <https://doi.org/10.2217/WHE.10.43>
- Ghosal, S., 2019. The Side Effects Of Metformin - A Review. *DMD* 6, 1–7. <https://doi.org/10.24966/DMD-201X/100030>
- Glintborg, D., Altinok, M.L., Mumm, H., Hermann, A.P., Ravn, P., Andersen, M., 2014. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. *J Clin Endocrinol Metab* 99, 2584–2591. <https://doi.org/10.1210/jc.2014-1135>
- Goldstein, S., Siddhanti, S., Ciaccia, A., Plouffle, L.J., 2000. A pharmacological review of selective oestrogen receptor modulators. *Human Reproduction Update*.
- Graham, G., Punt, J., Arora, M., Day, R., Doogue, M., Duong, J., 2011. Clinical pharmacokinetics of metformin. *Clin Pharmacokinetics*.
- Hart, R., Doherty, D., 2015. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. *J Clin Endocrinol Metab* 911–919.
- Homburg, R., Hendriks, M.L., König, T.E., Anderson, R.A., Balen, A.H., Brincat, M., Child, T., Davies, M., D'Hooghe, T., Martinez, A., Rajkhowa, M., Rueda-Saenz, R., Hompes, P., Lambalk, C.B., 2012. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. *Hum Reprod* 27, 468–473. <https://doi.org/10.1093/humrep/der401>
- Hughes, H., Collins, J., Vandekerckhove, P., 2000. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. *Cochrane Database Syst Rev*.
- Isojärvi, J., Laatikainen, T., Pakarinen, A., Juntunen, K., Myllylä, V., 1993. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. . . . N. 1993 Nov 4; 329(19):1383-8. *England Journal of Medical*.

- Jensen, A., Sharif, H., Frederiksen, K., Kjær, S.K., 2009. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. *BMJ* 338. <https://doi.org/10.1136/bmj.b249>
- Jensen, A., Sharif, H., Svare, E.I., Frederiksen, K., Kjaer, S.K., 2007. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. *Cancer Epidemiol Biomarkers Prev* 16, 1400–1407. <https://doi.org/10.1158/1055-9965.EPI-07-0075>
- Jonard, S., Dewailly, D., 2004. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. *Hum Reprod Update*.
- Kahyaoğlu, S., Yılmaz, B., Işık, A., 2017. Pharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literature. *Journal of the Turkish German Gynecological Association*.
- Kar, S., 2012. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. *J Hum Reprod Sci* 5, 262. <https://doi.org/10.4103/0974-1208.106338>
- Kar, S., Sanchita, S., 2015. Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: A randomized controlled trial. *J Hum Reprod Sci* 8, 197. <https://doi.org/10.4103/0974-1208.170373>
- Klepser, T., Kelly, M., 1997. Metformin hydrochloride: an antihyperglycemic agent. *Am J Health Syst Pharm*.
- Krauss, R., Siri, P., 2004. Metabolic abnormalities: triglyceride and low-density lipoprotein. *Endocrinol Metab Clin North America*.
- Lashen, H., 2010. Role of metformin in the management of polycystic ovary syndrome. *Ther Adv Endocrinol Metab* 1, 117–128. <https://doi.org/10.1177/2042018810380215>
- Legro, R.S., 2017. *Evaluation and Treatment of Polycystic Ovary Syndrome*. MDText.com, Inc.
- Legro, R.S., Arslanian, S.A., Ehrmann, D.A., Hoeger, K.M., Murad, M.H., Pasquali, R., Welt, C.K., Endocrine Society, 2013. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 98, 4565–4592. <https://doi.org/10.1210/jc.2013-2350>
- Legro, R.S., Barnhart, H.X., Schlaff, W.D., Carr, B.R., Diamond, M.P., Carson, S.A., Steinkampf, M.P., Coutifaris, C., McGovern, P.G., Cataldo, N.A., Gosman, G.G., Nestler, J.E., Giudice, L.C., Leppert, P.C., Myers, E.R., Cooperative Multicenter Reproductive Medicine Network, 2007. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. *N Engl J Med* 356, 551–566. <https://doi.org/10.1056/NEJMoa063971>
- Leon, L.I.R., Mayrin, J.V., 2020. *Polycystic Ovarian Disease*. StatPearls Publishing.
- McCartney, C.R., Marshall, J.C., 2016. Polycystic Ovary Syndrome. *N Engl J Med* 375, 54–64. <https://doi.org/10.1056/NEJMcp1514916>
- Moggetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E.,

- Muggeo, M., 2000. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J Clin Endocrinol Metab* 85, 139–146. <https://doi.org/10.1210/jcem.85.1.6293>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., Salehiniya, H., 2019. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health* 11, 287–299. <https://doi.org/10.2147/IJWH.S197604>
- Morin-Papunen, L., Rantala, A.S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., Tapanainen, J.S., 2012. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. *J Clin Endocrinol Metab* 97, 1492–1500. <https://doi.org/10.1210/jc.2011-3061>
- Mukherjee, S., Sharma, S., Chakravarty, B., 2010. Comparative evaluation of pregnancy outcome in gonadotrophin-clomiphene combination vs clomiphene alone in polycystic ovarian syndrome and unexplained infertility-A prospective clinical trial. *Journal of Human Reproductive Sciences* 3, 80. <https://doi.org/10.4103/0974-1208.69341>
- Nasri, H., Rafieian-Kopaei, M., 2014. Metformin: Current knowledge. *J Res Med Sci* 19, 658–664.
- Nazari, T., Bayat, R., Hamed, M., 2007. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. *Arch Iran Med* 10, 176–181. <https://doi.org/07102/AIM.0010>
- Nestler, J., 2008. Metformin for the treatment of the polycystic ovary syndrome. *2008;358:47-54. N Engl J Med*.
- Ng, E.H., Wat, N.M., Ho, P.C., 2001. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. *Hum Reprod* 16, 1625–1631. <https://doi.org/10.1093/humrep/16.8.1625>
- Nicandri, K., Hoeger, K.C., 2012. Diagnosis and treatment of polycystic ovarian syndrome in adolescents. *Opin Endocrinol Diabetes Obes*.
- Omran, M.Y.S., 2007. Metformin and Polycystic Ovary Syndrome. *Int J Health Sci (Qassim)* 1, 75–80.
- Ozdemir, S., Ozdemir, M., Gorkemli, H., Kiyici, A., Bodur, S., 2010. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. *Acta Obstet Gynecol Scand*.
- Patel, K., Coffler, M., Dahan, M., 2003. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. *J. Clin. Endocrinol. Metab*.
- Rocha, A.L., Oliveira, F.R., Azevedo, R.C., Silva, V.A., Peres, T.M., Candido, A.L., Gomes, K.B., Reis, F.M., 2019. Recent advances in the understanding and management of polycystic ovary syndrome. *F1000Res* 8. <https://doi.org/10.12688/f1000research.15318.1>
- Rostami-Hodjegan, A., Lennard, M.S., Tucker, G.T., Ledger, W.L., 2004.

- Monitoring plasma concentrations to individualize treatment with clomiphene citrate. *Fertility and Sterility* 81, 1187–1193. <https://doi.org/10.1016/j.fertnstert.2003.07.044>
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 81, 19–25. <https://doi.org/10.1016/j.fertnstert.2003.10.004>
- Roy, K., Baruah, J., Singla, S., Sharma, J., Singh, N., Jain, S., Goyal, M., 2012. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. *J Hum Reprod Sci* 5, 20. <https://doi.org/10.4103/0974-1208.97789>
- Sachdeva, G., Gainer, S., Suri, V., Sachdeva, N., Chopra, S., 2019. Prediction of Responsiveness to Clomiphene Citrate in Infertile Women with PCOS. *J Reprod Infertil* 20, 143–150.
- Sepilian, V., Nagamani, M., 2009. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. *BMJ*.
- Shackelford, D., Shaw, R., 2009. The LKB1- AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer*.
- Shannon, M., Wang, Y., 2012. Polycystic ovary syndrome: A common but often unrecognized condition. *J Midwifery Womens Health*.
- Shurrab, N.T., Arafa, E.-S.A., 2020. Metformin: A review of its therapeutic efficacy and adverse effects. *Obesity Medicine* 17, 100186. <https://doi.org/10.1016/j.obmed.2020.100186>
- Siddiqui, A., Khan, M., Zehra, T., Masood Ali, S.M., 2011. Efficacy and safety of metformin in over weight and obese patients with polycystic ovary syndrome. *Pakistan Journal of Medical Sciences* 27, 307–311.
- Speroff, L., Fritz, M., 2005. Induction of ovulation. In *Clinical Gynecologic, Endocrinology and Infertility* 7th edition. Philadelphia: Lippincott Williams and Wilkins.
- Strauss, J., 2003. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. *Ann NY Acad Sci*.
- Tariq, A., Mir, M.A., Babar, S., Akhtar, R., 2018. Pcos; Comparison Between Pioglitazone and Metformin for Ovulation in Patients. *Professional Medical Journal* 25, 568–572. <https://doi.org/10.29309/TPMJ/18.4295>
- Thatcher, S.S., Jackson, E.M., 2006. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. *Fertil Steril* 85, 1002–1009. <https://doi.org/10.1016/j.fertnstert.2005.09.047>
- Trabert, B., Lamb, E.J., Scoccia, B., Moghissi, K.S., Westhoff, C.L., Niwa, S., Brinton, L.A., 2013. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. *Fertil Steril* 100, 1660–1666. <https://doi.org/10.1016/j.fertnstert.2013.08.008>
- Trikudanathan, S., 2015. Polycystic ovarian syndrome. *Med Clin North America*.
- Tucker, G., Casey, C., Philips, P., 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. *British Journal of Clinical Pharmacology*.

- Tutakne, M., Chari, K., Valia, A., 2003. Textbook and atlas of dermatology. IADVL.
- Venkatesh, R., Gujral, G.S., Gurav, P., Tibrewal, S., Mathur, U., 2017. Clomiphene citrate-induced visual hallucinations: a case report. *J Med Case Rep* 11. <https://doi.org/10.1186/s13256-017-1228-0>
- Vink, J., Sadrzadeh, S., Lambalk, C., Boomsma, D., 2006. Heritability of polycystic ovary syndrome in a Dutch twin-family study. *Jornal Clinic Endocrinol Metab*.
- Wei, S., Jones, G., Thomson, R., Otahal, P., Dwyer, T., Venn, A., 2010. Menstrual irregularity and bone mass in premenopausal women: cross-sectional associations with testosterone and SHBG. *BMC Musculoskelet Disord*.
- Witchel, S.F., Oberfield, S.E., Peña, A.S., 2019. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. *J Endocr Soc* 3, 1545–1573. <https://doi.org/10.1210/js.2019-00078>
- Woolcock, J.G., Critchley, H.O.D., Munro, M.G., Broder, M.S., Fraser, I.S., 2008. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. *Fertil Steril* 90, 2269–2280. <https://doi.org/10.1016/j.fertnstert.2007.10.060>